Erythromycin alert for patients with prolonged QT interval

Clinical

Erythromycin alert for patients with prolonged QT interval

In Clinical

Erythromycin should not be given to patients with a history of QT interval prolongation or ventricular cardiac arrhythmia, or patients with electrolyte disturbances, says a Drug Safety Update from the MHRA.

A potential drug interaction between rivaroxaban and erythromycin resulting in increased risk of bleeding has also been identified.

A European review of safety data has highlighted an increased risk of cardiotoxicity with macrolide antibiotics, particularly erythromycin. As a result, the product information for erythromycin is being updated in line with that for clarithromycin to include warnings regarding the risk of QT interval prolongation and fatal arrhythmia.

A new contraindication has been added for those with risk factors for QT interval prolongation and arrhythmia, including for patients with a history of QT interval prolongation or ventricular arrhythmia and patients with electrolyte disturbances. Warnings have also been strengthened on the risk of cardiac events and risk factors.

Clinicians should be aware of the increased short-term risk of adverse cardiac outcomes, says the MHRA, so that the benefits and risks of treatment can be fully evaluated at the time of treatment initiation. This should be especially considered in patients with coronary artery disease, severe cardiac insufficiency, conduction disturbances, or clinically relevant bradycardia.

Caution should be exercised in patients concomitantly taking other medicinal products associated with QT interval prolongation, and in patients who are elderly since these groups may be more susceptible to drug-associated effects on the QT interval.

Patients should be informed of the signs and symptoms of cardiac events and be advised to seek medical advice should they occur. Warnings on the signs and symptoms of cardiac events have been added to the patient information leaflet.

Rivaroxaban drug interaction

The European review also concluded that rivaroxaban should be included as an example of a potential interaction between erythromycin and oral anticoagulants in the product information since this interaction could lead to increased risk of bleeding.

Erythromycin inhibits CYP3A4 and P-gp and can lead to an increase in the maximum blood concentration of rivaroxaban.

Rivaroxaban is not the only direct-acting oral anticoagulant (DOAC) to interact with macrolide antibiotics. With edoxaban, dabigatran and apixaban concomitant administration of P-gp inhibitors (and for apixaban, also CYP3A4 inhibitors) is expected to result in increased plasma concentrations.

Record my learning outcomes

Clinical

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
Clinical

Improving treatment of constipation

There is an urgent need to improve bowel care and the management of constipation, and not only to relieve patient distress.

10 Min Article

bookmark_icon_off
Clinical

Swallowable sponge could reduce need for endoscopies

In trials just one in 30 of the patients offered the Cytosponge were referred for an endoscopy.

2 Min Article

bookmark_icon_off
Clinical

Clinical briefing: A health literate public?

The Government wants people to take more responsibility for their own health but are there knowledge gaps?

7 Min Article

bookmark_icon_off
Clinical

Signs of success with MenB vaccination programme

Infant vaccination against group B meningococcal disease (MenB) has resulted in a significant decline in cases.

2 Min Article

bookmark_icon_off
Clinical

Older people's health

Older people may have been seen less often in pharmacies because of Covid – but out of sight shouldn’t mean out of mind. 

27 Min Article

bookmark_icon_off
Clinical

More tariff changes on the way?

A consultation on medicines reimbursement could see further tightening of price controls in the specials market, but the timetable is uncertain...

12 Min Article

Recommended Learning

bookmark_icon_off
Sponsored Education

Challenge your thinking on warts and verrucas

Discover different treatment options for warts and verruas and when to recommend them to your customers, based on their individual needs

20 Min Module

bookmark_icon_off
Bayer Business Programme

Let's talk tech: Using technology to drive your business

This training offers insights into making the most of technology and the commercial opportunities this can offer your business.

 

18 Min Module

bookmark_icon_off
Bayer Business Programme

Make it Count: Manager version

This training offers new insights into the customers of today and explores how you and your team can adapt your sales approach to engage with customers in order to grow your business.

15 Min Module

bookmark_icon_off
Sponsored Education

Next-level parasite protection for dogs

Explore the FRONTLINE Tri-Act® active pack to learn about next-level parasite protection for dogs.

5 Min Module

bookmark_icon_off
Sponsored Education

Supporting women in their contraceptive choices

Upgrade your contraceptive consultations by exploring the interactive pack to learn about a daily oral contraceptive pill

8 Min Module

bookmark_icon_off
Sponsored Education

Helping customers treat & care for their scalp

Understanding the causes and symptoms of some common scalp conditions will help you to make a real difference to your customers’ lives. Complete this module to discover self-care and product advice to help ease symptoms and maintain scalp health.

24 Min Module